Put company on watchlist
Zentrogene
ISIN: KYG7785S1075
WKN:
About
Company Snapshot
New: Activate notification
Be informed about new publications
New: AI Factsheet

Coming soon: Summary of the company message by AI/p>

Zentrogene · ISIN: KYG7785S1075 · Newswire (Company)
Country: Hongkong · Primary market: Cayman Islands · EQS NID: 2196570
12 September 2025 06:30AM

Hong Kong Lab Zentrogene Cracks Twin DNA Code; Gender Mystery Solved for Moms Worldwide



EQS Newswire / 12/09/2025 / 06:30 CET/CEST

HONG KONG SAR - Media OutReach Newswire - 12 September 2025 - Zentrogene Laboratory, an international genetic testing institution based in Hong Kong (under Sanai Health Industry Group 01889.HK), announced the launch of its 'Y Precision' testing technology based on Next-Generation Sequencing (NGS). This locally developed innovation in Hong Kong addresses longstanding industry challenges in gender determination for twin pregnancies. It overcomes the limitations of traditional qPCR platforms, achieving the first-ever precise identification of male-female twins while significantly enhancing the accuracy of fetal cell-free DNA (cfDNA) analysis.

671820-image-1-png-550x.png
Illustration: IP Image Ambassador Dr.z

Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures. Zentrogene's NGS-based technology achieves three breakthroughs:
  1. Fetal Signal Assessment: Utilizes whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals.
  2. Contamination Identification: Differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals.
  3. Twin Pregnancy Precision Analysis: Independently analyzes X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins.
As a pioneer in Hong Kong's genetic testing field, Zentrogene has established a global technology matrix covering pre-pregnancy, prenatal, and oncology applications through its integrated Sanger sequencing and NGS platforms. This NGS breakthrough underscores its 'Technology-Driven Globalization' strategy, leveraging Hong Kong's expertise to deliver precision medical solutions worldwide. Zentrogene continues to advance genetic technology, safeguarding every family's hopes with scientific rigor.

For details, visit:
https://www.zentrogene.com/
https://www.zentrogene.com.hk/

Official Cooperation Contacts:
Telephone: +86 18051865085 (WeChat same number)
Telegram: +855 99990026
Facebook: Zentrogene

Hashtag: #Zentrogene

The issuer is solely responsible for the content of this announcement.

225647
News Source: Zentrogene

12/09/2025 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

smart.AD

Trading Solutions for Professionals

  • 25 kinds of clusters
  • 26 world exchanges
  • 14 different charts
  • 58 necessary for analysis indicators
  • 50+ customized templates for charts


Get your free Demo today

© 2025 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2025 WEBs Investments ETFs
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Saturday, 13.09.2025, Calendar Week 37, 256th day of the year, 109 days remaining until EoY.